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Zidovudine to prevent mother-to-infant HIV trans-
mission in developing countries:a view from
Thailand
Sirs, The title of the September 1998 editorial of Tropical
Medicine and International Health asks, ‘Zidovudine to
prevent mother-to-infant HIV transmission in developing
countries: any questions?’ (Van der Stuyft et al. 1998). We are
ﬁve nurses, a social worker and a doctor working with
(mostly poor) HIV-infected pregnant women in Bangkok and
we would like to balance the technocratic approach of the
editorial with a view from the ﬁeld.
There are arguments in the editorial which are implied
rather than clearly stated. These implications need to be clari-
ﬁed before the authors can embark on the critical appraisal
which is their stated objective. There is the implication that
providing short-course zidovudine (ZDV) is tantamount to
sacriﬁcing the mother’s life in order to preserve that of the
baby. Surely this is an exaggeration. Bridging the HIV
control/AIDS care gap is described as a noble aim, but is dis-
missive of an initiative to reduce mother-to-child perinatal
transmission in developing countries. We think that this par-
ticular initiative is about the only thing to emerge from the
12th World AIDS Conference which has some potential to
narrow (slightly) the gap. Serious concerns are raised about
the Bangkok perinatal ZDV study (Vuthipongse et al. 1998).
These concerns are then dismissed without further discus-
sion, even though the results of this study will have wide
implications for policy in many countries. For example,
following publication of results from the Bangkok perinatal
ZDV study, UNAIDS, UNICEF and WHO launched a new
initiative to limit mother-to-child transmission in 10 develop-
ing countries in Africa and Asia (WHO 1998). The implica-
tions of the editorial are dangerous because they carry the
authority of an expert journal and the respected institutions
with which the authors are afﬁliated.
The remainder of the editorial is clearly expressed opinion,
referring to less developed countries as a uniform mass. Less
developed countries are not all the same. Thailand has made
a strong national response to AIDS (Phoolcharoen et al.
1998). Programmes to provide antiretroviral drugs (mono-
therapy and bitherapy) between 1992 and 1995 were costly
with low effectiveness. A working team recommended in 1995
that antiretrovirals be reallocated to prevent vertical transmis-
sion (Phoolcharoen et al. 1995).
We share the editorial’s concern about treatment for the
mother after delivery. We know of a participant in the
Bangkok perinatal ZDV study who has recently died. She had
symptomatic HIV infection when she ﬁrst presented to an
obstetrician in one of the CDC collaborating hospitals and
was enrolled in the study. There was an eight-month delay
before she was referred to a physician for investigation and
treatment of her symptomatic HIV infection. For us as carers,
it is difﬁcult to accept the concept of researching a patient’s
condition without taking on responsibility for care and treat-
ment.
Although there is a lack of tradition in many developing
countries of structures to address ethical issues (Adler 1997),
in Thailand these structures do exist and follow western mod-
els. The expatriate research industry and funding agencies
have a responsibility to apply ethical standards to their work
wherever it is done. Thai patients are being increasingly used
for HIV/AIDS research. The research industry and funding
agencies therefore have a particular responsibility in Thailand
not to establish unethical precedents.
What is the next step for Thai women and their children,
now that a study involving participation of HIV-infected
pregnant Thai women has been published? Women need
information to help them make the right choice for their situ-
ation. As can be seen from the above case, ethical problems
do indeed remain to be considered, in particular how to set
up a comprehensive model of care that pays attention to
women’s other health problems. However, the fact that AIDS
programmes in countries such as Thailand are vertical rather
than comprehensive is a donor-driven phenomenon.
Maybe the most important ethical consideration is the
price of the drugs. The editorial refers to the generosity of
the pharmaceutical industry in reducing the price of ZDV .
How generous is Glaxo-Wellcome really being? The Wall
Street Journal estimates that another 60 million US dollars a
year will be added to Glaxo-Wellcome’s revenue as a result of
its generosity in ‘discounting’ ZDV for developing countries
following publication of the Bangkok study results (Waldholz
1998). Should some of this 60 million dollars go towards pay-
ing for more generous support or care for study participants
and their children?
A. Kumphitak, P. Cawthorne, S. Lakhonphol,
S. Kasi-Sedapan, S. Sanaeha, N. Unchit and D. Wilson
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Zidovudine against mother-to-child HIV trans-
mission
Sirs, In their editorial about the use of zidovudine to prevent
mother-to-infant HIV transmission in developing countries,
Van der Stuyft et al. (1998) mention the many obstacles to
implementing such a programme and question the feasibility,
acceptability, efﬁcacy and cost of this intervention. We regret
that the authors do not propose solutions to the incredible
injustice that in industrialized countries we are well on our
way to ﬁnding a cure for HIV infection while poor countries
cannot even afford short-course therapy to prevent perinatal
transmission of HIV . The question is not whether or not we
should introduce antiretrovirals (ARVs) in resource-poor
countries – the drugs are already available there, albeit only
to a limited number of individuals at a very high price – and
the pressure to obtain them will continue to increase. Cer-
tainly women will do everything they can to have a healthy
child.
We agree that in order to use ARVs effectively and safely in
low and medium-income countries, health services, including
those for pregnant women, should be improved. Now, with
the results of the Thailand study (Vuthipongse et al. 1998)
showing the protective effect of zidovudine in preventing peri-
natal transmission of HIV , we have an excellent reason to do
so. Initially zidovudine should be offered in situations where
adequate care for pregnant women is already available or eas-
ily improved (for example, in medium-income countries or in
health care facilities of large companies in resource-poor
countries). This would provide valuable experience for large-
scale introduction of ARVs.
It is difﬁcult to prove, but we believe that AIDS research
and AIDS control activities have had a positive effect on the
control of other health problems: because of AIDS there is
now increased interest in improving sexually transmitted dis-
ease and tuberculosis control programmes. AIDS boosted
research in virology, immunology, pharmacology, epidemi-
ology and social sciences. Development times for new drugs
have been shortened. Hopefully, ongoing research of peri-
natal HIV transmission will lead to improved mother and
child health care in general.
As physicians, rather than accept that health care budgets
are divided for disease control according to the cost per
DALY, we should ﬁght to increase total health care budgets.
More than 10 years of AIDS activism have shown that if HIV-
infected individuals join forces with health care workers and
scientists, politicians can be swayed and new donors found.
People with HIV infection in poor countries should realize
that potentially they are an enormous political force. Much
has been achieved in the ﬁght against HIV infection in a rela-
tively short period of time, but not enough is reaching
resource-poor countries. We cannot stop now. During the last
years political leaders have made commitments: Clinton
promised an HIV vaccine within 10 years, Chirac pledged to
make ARV treatments available in Africa. At the next World
AIDS Conference in Durban in the year 2000 we shall see how
much of this has been accomplished.
R. Colebunders and Y. Coppieters
Institute of Tropical Medicine, Antwerp, Belgium
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Zidovudine to prevent mother to infant HIV trans-
mission in developing countries:many questions!
Sirs, We completely agree with the reaction of Kumphitak
et al. (1998) to our editorial (Van der Stuyft et al. 1998). With
one restriction: an in-depth discussion of the methodological
caveats vis-a-vis the Bangkok perinatal Zidovudine study
(Vuthipongse 1988) was – apart from not being our purpose –
superﬂuous in the light of the CDC editorial accompanying
the MMWR report on it. We acknowledge that a number of
developing countries do fulﬁl the necessary prerequisites to
successfully implement Zidovudine-centred control pro-
grammes of mother to infant HIV transmission. We also
appreciate that the authors share our reservations with regard
to the cost-effectiveness of such programmes and their opera-
tional feasibility.
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Most importantly, we are grateful that they substantiate
our ethical considerations and our concern for the fate of the
seropositive mothers. It may be noted in passing that the pre-
liminary results of the PETRA-trial (37% reduction of verti-
cal transmission after an antiretroviral regimen at delivery
followed by a one week regimen for both newborn and
mother – presented on 1 February 1999 at the Sixth Con-
ference on Retroviruses, Chicago) do not substantially affect
the nature of these apprehensions.
We also appreciate and support Colebunders and
Coppieters (1999) militant activism for the rights of AIDS
patients all over the world. However, we do not agree with
their assumptions and premizes on what constitutes the most
effective health care model and the best political strategy to
achieve more equity. Kumphitak’s letter eloquently addresses
the inherent drawbacks of vertical programmes, which have
never been demonstrated to generate positive spin-off effects
for the control of nontargeted health problems. Furthermore,
health policy decisions driven by political eagerness to
demonstrate commitment to the ‘affordable’ should not be
encouraged, but countered with scientiﬁc evidence on what
constitutes the right agenda. We fear that the current excite-
ment about a tool that works will detract energy and re-
sources while the key issues in AIDS research and control still
remain unresolved. In view of the huge numbers of at risk
and infected people in the developing world, the priority in
AIDS research remains the search for a vaccine (Anonymous
1998) and for affordable treatment regimens for all HIV-
infected people (UK NGO Consortium 1998). Survival of
AIDS patients in the developing world has not improved, and
will not do so, as long as effective drugs are inaccessible.
Should this problem not be tackled at its roots instead of
shifting into seemingly rewarding programmes?
It was our intention to signal, somewhat provocatively, that
the Bangkok perinatal Zidovudine trial raises quite a few
questions that deserve thoughtful consideration. Some under-
statements on the ‘generosity’ of the pharmaceutical industry,
among others, may not have been fully appreciated, but our
more outspoken challenges seem to have elicited the reﬂection
we hoped for.
Patrick Van der Stuyft*, Marleen Boelaert  and
Marleen Temmermanà
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Relationship between histopathological ﬁndings
and phylogenetic divergence in Trypanosoma cruzi
Sirs, recently de Diego et al. (1998) showed in an interesting
study that different genotypes of Trypanosoma cruzi can
provoke distinct histopathological lesions in the mouse. The
authors draw special attention to the varieties of cardiac and
brain tropism of T. cruzi and conclude that the histological
patterns found in the experiments could explain, in part,
differences of the clinical features of patients with Chagas’
disease. We would like to remember that these experimental
results are not only consistent with the well-known varieties
of the clinical appearance in patients but also with the differ-
ences of the morphological ﬁndings in patients suffering from
Chagas’ disease.
We studied the histopathologic pattern in patients with
chronic Chagas’ disease, who suffered lethal reactivation
caused by a secondary immunodeﬁciency during chemother-
apy (in patients with malignant neoplasms) or provoked by
infection with HIV (Metze et al. 1991, 1993; Metze & Maciel
1993). Careful and detailed histological examinatons of the
organs at autopsy, complemented by immunohistochemical
or electron microscopic studies when necessary, disclosed
three distinct forms of reactivation: (i), acute Chagas’ menin-
goencephalitis with the presence of pseudocysts, but without
myocarditis and without areactive pseudocysts of T. cruzi in
the myocardium; (ii), acute reactivated chronic Chagas’
myocarditis with abundant pseudocysts but no cerebral
lesions (neither inﬂammatory alterations nor necrosis or
pseudocysts); and (iii), acute Chagas’ menigoencephalitis and
reactivated myocarditis, both with the presence of pseudo-
cysts of T. cruzi.
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To explain these results we postulated that differences of
the histological pattern of reactivated Chagas’ disease could
have been caused by varieties of the tissue tropism of T. cruzi
(Metze & Maciel 1993). This is in accordance with the inves-
tigations of de Diego et al. (1998) who revealed that genotype
20 showed a marked tendency to encephalitic lesions in mice
with liqueﬁed necrosis but only scanty foci in the heart,
whereas 83% of studied stocks of genotype 39 showed
pseudocysts in the heart, but fewer lesions in the brain.
In summary, we think that the animal experiments con-
ducted by de Diego et al. (1998) corroborate well our previ-
ously postulated hypothesis, which had been established on
histological ﬁndings of patients with recrudescence of
Chagas’ disease.
Konradin Metze and Irene Lorand-Metze
Faculty of Medicine, POB 6111, State University of Campinas,
BR 13081–970 Campinas-SP, Brazil
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Clinical and biological manifestations of dengue
Sirs, in their analysis of clinical and biological manifestations
of dengue in the November issue, Deparis et al. (1998) con-
clude that the ‘association of macular rash, pruritus, low
platelet count and leukopenia is clinically not predictive of
dengue fever’. We think this conclusion should be modiﬁed.
Clinical signs and symptoms almost never are 100% predic-
tive or pathognomonic of a disease. Instead, we look for rela-
tive proofs of the presence or absence of disease, represented
by their positive and negative likelihood ratios. The two com-
bined constitute the odds ratio, which gives a fair representa-
tion of the overall discriminatory value of a sign or symptom
(Dujardin et al. 1994). Odds ratios and likelihood ratios are
determined on the basis of cases and controls who belong to
the same population, e.g. ‘all patients with fever’, ‘all patients
presenting with fever and myalgia’. In this study the deﬁnition
of the inclusion criteria as ‘all patients in whom the diagnosis
of dengue was suspected’ is not only too vague a description
for estimation of likelihood ratios that can be extrapolated to
other clinical situations, but moreover, inclusion criteria are
subsequently themselves analysed for their predictive power.
As some clinical signs contribute to suspicion, such as macu-
lar rash and pruritus, patients presenting such signs are more
likely to be enrolled in the study, both for dengue and non-
dengue groups. Obviously this may be confounding by
decreasing the speciﬁcity of the concerned arguments.
In contrast to what the authors ascertain, we could not ﬁnd
a true analysis of the value of the association of the four key
signs. The positive predictive value is given for ‘the clinical
diagnosis’, without speciﬁcation, and the presentation of the
utility of the results of the logistic regression is based on an
‘and/or’ string of four characteristics, which is not correct. It
would mean that the presence of only one of the four symp-
toms e.g. pruritus, would increase the probablity of dengue,
notwithstanding the absence of the others. Further analysis
might have revealed that the combination of three or four
signs predicts almost perfectly dengue fever, or that absence
of one or two signs excludes it.
It should be emphasized that the positive predictive value
the authors found is quite high, at least partially thanks to to
the high pretest probability in case of an epidemic. However,
for the diagnosis of dengue fever we need a certainty of
100%, as most cases have a relatively mild course and therapy
is absent (Kassirer 1989). The only advantage of a clinical
diagnosis would be the warning of risk of complications.
Therefore, the problem is not to decrease the false positive
rate of the clinical diagnosis which is already low (1/3), but
rather to decrease the false negative rate, i.e. dengue cases
wrongly excluded from the physicians’s diagnosis. If there is
no clinical characteristic with a good negative likelihood ratio
(LHR-), any fever should be considered to be dengue during
an epidemic.
In conclusion, we agree that the inclusion criteria permit
calculation of the positive predictive value of a clinical diag-
nosis of dengue fever relative to the gold standard of labora-
tory conformation, but we disagree that they are appropriate
for analysis of the predictive value of disease characteristics.
Further, no true analysis of the association of clinical signs
was worked out. Finally, as the diagnostic threshold is rather
low, research efforts should concentrate on avoiding false
negatives, hence on ﬁnding clinical signs with a signiﬁcant
negative likelihood ratio.
J. Van den Ende* and L. Lynen 
*Institute of Tropical Medicine, Antwerpen, Belgium
†ZenoBisofﬁCentro per le Malattie Tropicali, Negrar,
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Towards a kala azar risk map for Sudan:mapping the potential
distribution of Phlebotomus orientalis using digital data of
environmental variables
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Page 110: Figure 2. Due to a typographical error the legends for panels a, b and d and the labels for panel d were omitted. Figure
2, including the legends and labels, is reproduced opposite.